Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi.
Chief Executive Officer Claude Maraoui said the company generated positive EBITDA in the second quarter and
Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Fortress Biotech (NASDAQ: FBIO) saw its stock plunge over 30% on October 1, 2025, following the U.S. Food and Drug Administration's (FDA) issuance of a Complete Response Letter (CRL) for its New Drug Application (NDA) for CUTX-101. This investigational treatment, developed for pediatric patients suffering from the rare genetic
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 blocker for advanced cSCC.
Fortress Biotech shares are trading lower by 20% Friday afternoon. The company announced the pricing of a $8 million registered direct offering and concurrent private placements.
